item management s discussion and analysis of financial condition and results of operations management s discussion and analysis of financial condition and results of operations general the company was incorporated in and went public in as possis machine corporation 
initial operations consisted of design  manufacturing and sales of industrial equipment and a division that provided temporary technical personnel 
the company s involvement with medical products began in  when it sold its rights to a patented bileaflet mechanical heart valve  which it had obtained from zinon c 
possis  the founder of the company  to st 
jude medical  inc for royalty payments based on st 
jude s valve sales the st 
jude royalties 
see note of notes to consolidated financial statements 
in a subsidiary was established to focus initially on the development of a synthetic blood vessel used to bypass blocked coronary arteries 
in the late s the company decided to leverage existing management expertise and entered the pacemaker lead business 
the strategic role of the pacemaker lead business was to provide cash flow to fund the development of synthetic grafts and thrombectomy systems and to give the company access to and name recognition within the medical device industry 
in the company made the decision to focus on medical products and subsequently divested all non medical operations  beginning with its technical services division in september followed by its industrial equipment subsidiary and related land and buildings in january see note of notes to consolidated financial statements 
in march the company sold its pacemaker lead business because it anticipated that revenues from this business would decrease due to a pacemaker lead technology shift 
in connection with this sale  the company received million in cash and the right to receive royalty payments over a twelve month period 
see note of notes to consolidated financial statements 
the sale of the pacemaker lead business in march enabled possis to focus its human and financial resources exclusively on its other products  which are currently in clinical trials and in early stages of commercialization 
over the past several fiscal years  the company has transitioned its revenue stream from pacemaker leads and royalty revenues to revenues from the sale of its new products and related sales agreements 
the resulting cash flow  together with the approximately million net proceeds from the company s calendar and common stock offerings  has been used to fund the company s operations  including research and development related to its products 
with the sale of its pacemaker lead business and the expiration of royalty payments from st 
jude in march  possis does not expect to become profitable unless it achieves significant sales in the united states and its products receive additional united states food and drug agency fda marketing approvals 
there can be no assurance that significant sales or additional marketing approvals will occur 
results of operations fiscal years ended july   and total revenue increased in fiscal and decreased in fiscal  compared to prior years 
the main factor in the product sales increase in fiscal was the december fda clearance to commence us marketing of the angiojet rapid thrombectomy system  with labeling claims for removal of blood clots from grafts used by patients on kidney dialysis 
the angiojet system drive unit is a piece of capital equipment and currently lists for  to us hospitals 
the purchasing cycle for the angiojet system drive unit  the company believes  will average nine to twelve months depending on the customer s budget cycle 
the company offers an angiojet system evaluation program lasting up to days during which  in return for free placement of the drive unit  the hospital purchases a minimum number of disposable catheters and pumps 
if the hospital requires additional time to complete the purchase and chooses to keep the drive unit  monthly rent is charged with a portion of rent paid applied to the final purchase price 
drive unit rental programs are available and  through a third party  the company offers various drive unit financing plans including prime interest rate capital leases  operating leases and a plan to acquire the drive unit through the purchase of a minimum number of marked up disposable products 
angiojet system drive unit and disposable product sales in the us during fiscal were  and  respectively 
foreign sales of the angiojet system  drive units and disposable products  during fiscal  and were   and  respectively 
the company s german angiojet system distributor was terminated in february which impacted fiscal foreign sales 
the company is evaluating its european angiojet system distribution options 
the company believes that us angiojet system sales will grow through the addition of sales people  the completion of clinical trials designed to yield additional label approved product uses and the introduction of additional catheter designs 
during fiscal  and  sales of the perma flow coronary bypass graft were   and  respectively 
baxter healthcare corporation  the company s perma flow graft worldwide distribution partner since march  has developed marketing materials and in october officially launched the product within the european market following the receipt of ce mark approval for the perma flow graft in july the perma flow graft was the first synthetic coronary bypass graft to clear this significant european regulatory milestone 
in addition  the company plans to submit an application to the fda by december requesting that the perma flow graft be given humanitarian device exemption status  thereby allowing the company to market the product in the us for a limited indication as it completes the us clinical study and pma registration designed to provide broad marketing approval 
due to the termination of the company s worldwide perma seal dialysis access graft distributor in january  sales of this product in fiscal were only  perma seal graft sales in fiscal and were  and  respectively 
until another distributor is selected  there will likely be no perma seal graft product sales 
the company is seeking another distributor for this product and is in discussion with several potential companies 
the company submitted a k application to the fda in august seeking clearance to market the perma seal graft in the united states 
sales agreement and other revenue includes  per year for fiscal and from baxter healthcare corporation due the company under a supply and distribution agreement for the perma flow coronary bypass graft 
in addition  fiscal sales agreement and other revenue includes  in cash and returned unused product due to the termination of the company s perma seal graft supply and distribution agreement 
the company received  through july  from it s perma seal graft distributor 
see note of notes to consolidated financial statements 
the company is planning for continued growth in product sales for fiscal and beyond and believes that for the next several years most of this growth will come from angiojet system sales in the us marketplace 
cost of medical products decreased in fiscal and increased in fiscal  compared to prior years 
production expenses relating to vascular grafts were   and  for fiscal years   and  respectively 
during most of fiscal the company has worked to validate the vascular graft production processes and was not producing graft products 
the cost of product and process validation is reported as research and development expense 
angiojet system production costs for fiscal  and were   and  respectively 
the increase is primarily due to significant growth in angiojet system product sales 
the company believes that manufacturing costs per unit will be reduced as product sales and related production volumes grow and as identified product and process improvements are made 
in april the company received full iso quality system certification 
iso certification is issued by the international standards organization and incorporates standards of quality and excellence recognized worldwide in design  development  production  installation and service 
selling  general and administrative expenses increased in fiscal and in fiscal  compared to prior years 
the primary factor in fiscal is increased sales and marketing expense related to the establishment of a direct us sales organization to sell the angiojet rapid thrombectomy system and expenses of marketing the product in the united states 
based upon early physician interest  the company has grown the us angiojet system sales and marketing organization from eight employees in january to employees in july the company plans to at least double its field sales organization during fiscal and sales and marketing expenditures are expected to grow significantly in the current year and beyond 
in fiscal  the primary factor in the growth in selling  general and administrative expense was increased sales and marketing expenditures necessary to broaden non us distribution and to prepare for fda marketing clearance of the angiojet system 
research and development expenses increased in fiscal and decreased in fiscal  as compared to prior periods 
fiscal increases are due primarily to vascular graft product and production process validation expenses and increased expenses of conducting the perma flow graft and coronary angiojet system clinical trials 
the company believes that research and development expenses will continue to increase as it completes the development of its current products  invests in development of new angiojet rapid thrombectomy system applications  new vascular grafts and new angiojet technology based products 
interest income has decreased in fiscal from the previous year due to use of the company s cash reserves to fund the company s operations 
the company recorded the final income relating to the sale of its technical service division during the first quarter of fiscal liquidity and capital resources the company s cash  cash equivalents and marketable securities totaled approximately million at july   a decrease of million from the prior year 
the primary factor in the reduction of the company s cash position was the net loss of approximately million 
during fiscal  cash used in operating activities was million  which resulted primarily from an million net loss and a million increase in receivables  inventories and other current assets  offset by depreciation  amortization of goodwill  stock compensation and an increase in trade accounts payable and accrued liabilities totaling million 
cash provided by investing activities was million  which resulted from the net proceeds from the sale maturity of marketable securities of million  offset by additions to plant and equipment of  net cash provided by financing activities was  which resulted primarily from the exercise of stock options of  during fiscal  cash used in operating activities was million  which resulted primarily from an million net loss and a million increase in receivables  inventories and other current assets  offset by depreciation  amortization of goodwill  stock compensation and an increase in trade accounts payable totaling million 
cash used in investing activities was million  which resulted primarily from net purchases of marketable securities of million and additions to plant and equipment of million  offset by the proceeds from the sale of discontinued operations of  fiscal additions to plant include approximately million associated with the company s april relocation to a larger leased facility 
proceeds from discontinued operations increased  in fiscal as a result of the prepayment by advanced technical services  inc ats of the notes receivable and estimated remaining royalty payments in connection with the sale of ats 
see note of notes to consolidated financial statements 
net cash provided by financing activities resulted primarily from the company s october common stock offering netting approximately million 
during fiscal  cash used in operating activities was million  which resulted principally from the net loss of million and a decrease in accrued and other current liabilities of million  offset by depreciation  amortization of goodwill and stock compensation totaling  and a decrease in accounts receivable of million 
cash used in investing activities was million  which resulted primarily from net purchases of marketable securities of million and additions to plant and equipment of  offset by proceeds from the sale of discontinued operations of  net cash provided by financing activities of million resulted principally from the september common stock offering of million  the exercise of stock options of  and proceeds from notes payable of  offset by the repayment of long term debt of  the company believes that product sales of the angiojet system in the us and internationally will yield meaningful sales growth going forward 
at the same time  sales and marketing expenditures will continue to increase with the sales growth 
research and development expenditures are expected to grow as well 
the company expects to report a loss for fiscal in addition  the company expects that increasing working capital investments in trade accounts receivable and inventory will be required to support growing product sales 
the company is currently evaluating its capital needs and the options available for raising cash 
additional capital will likely be sought in fiscal forward looking statements this management s discussion and analysis of financial condition and results of operations and certain other sections of this k  contain certain forward looking statements as defined in the private securities litigation reform act of such statements relating to future events and financial performance  including the submission of applications to the fda  revenue and expense levels and future capital requirements  are forward looking statements that involve risks and uncertainties  including the company s ability to meet its timetable for fda submissions  the review time at the fda which is out of the company s control  changes in the company s marketing strategies  the company s ability to establish product distribution channels  changes in manufacturing methods  market acceptance of the angiojet system  changes in the levels of capital expenditures by hospitals  the levels of sales of the company s products that can be achieved and other risks detailed from time to time in the company s various securities and exchange commission filings 

